Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a U.S. biopharmaceutical company built around XPO1 inhibition, with XPOVIO (selinexor) as its commercial product. It develops and commercializes cancer therapies, while also monetizing its science through licensing arrangements with partners such as Menarini and Antengene.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueXPOVIO sales in the U.S., the company's only product revenue source.
Milestones, reimbursements and other payments from partners such as Menarini and Antengene.
KaryForward® provides reimbursement navigation, copay support and nurse case management.
Products
Reported · share of revenue- Products78.6 %
- License and Other21.4 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Karyopharm sells primarily to U.S. patients through the prescription channel, with physicians and healthcare providers driving treatment decisions for XPOVIO. Third-party payors are critical because reimbursement, prior authorization and gross-to-net adjustments materially affect access and realized revenue. The company also serves licensing partners that commercialize or develop selinexor outside the U.S.
Physicians prescribe XPOVIO for eligible cancer patients, while patients use the drug and rely on support services to access therapy.
Commercial insurers and government programs influence access, copay burden and net realized product revenue.
Partners such as Menarini and Antengene pay for development support, milestones and regional rights to selinexor.
Clinics and hospitals dispense XPOVIO and are relevant to inventory, returns and reimbursement processes.
Strategy
Karyopharm's strategy is to extend the commercial life of XPOVIO in the U.S. while advancing selinexor into additional cancer indications, including myelofibrosis. At the same time, management is actively evaluating financing and strategic alternatives to address liquidity pressure and preserve value. Partnered development and ex-U.S. licensing remain important to monetizing the platform with limited internal capital.
Product revenue is the company's main operating cash source and the core of the business model.
New indications are needed to expand the addressable market and reduce dependence on one product.
Liquidity constraints and debt maturities create going-concern pressure.
Licensing revenue diversifies funding and extends the platform without full commercial buildout.
Geography
The business is overwhelmingly U.S.-centric today: management states that all product revenue to date has come from U.S. sales of XPOVIO. International exposure is mainly indirect through licensing partners, which creates some non-U.S. revenue but limited direct commercial footprint. This concentration makes U.S. reimbursement, prescribing trends and regulatory dynamics the key geographic drivers of performance.
Risks
The company is highly dependent on XPOVIO, so any slowdown in prescribing, reimbursement pressure or competitive displacement would quickly affect revenue and cash flow. Liquidity and debt obligations are a major company-specific risk, with management explicitly stating substantial doubt about going concern. As a cancer drug developer, Karyopharm also faces clinical, regulatory and commercialization risk typical of biotech, including trial failure, delayed approvals and pricing pressure versus generics and newer therapies.
- Going concern and liquidity shortfallImpact: CriticalLikelihood: High
Management disclosed substantial doubt about continuing as a going concern and limited cash relative to debt obligations.
Exposure: Debt maturities and minimum liquidity covenants
- Dependence on XPOVIO commercial successImpact: HighLikelihood: High
The company states its business is substantially dependent on XPOVIO, so any loss of market acceptance would materially hurt revenue.
Exposure: U.S. oncology sales
- Competitive pressure in oncologyImpact: HighLikelihood: High
Competing branded and generic therapies may be more effective, safer, more convenient or less costly.
Exposure - Regulatory and clinical development failureImpact: HighLikelihood: High
Pipeline value depends on successful trials and approvals, which are uncertain and time-consuming.
Exposure: Selinexor development programs
- Pricing and reimbursement pressureImpact: MediumLikelihood: High
Third-party payors can limit access and the product is priced at a premium to generics.
Exposure: U.S. commercial market
Accounting
Judgemental itemsNet product revenue depends on estimates for returns, rebates, chargebacks and other deductions.
Impact: Can materially change reported XPOVIO sales and quarterly comparability
Milestones and development reimbursement from Menarini and Antengene are recognized as earned and can be lumpy.
Impact: Creates volatility in collaboration revenue
Financing actions can trigger gains/losses, fees and interest expense changes.
Impact: Affects net loss and capital structure presentation
Valuation changes depend on stock price and other assumptions.
Impact: Can create non-cash earnings volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
Kairos Pharma, LTD.
KAPA · Pharmaceutical Preparations
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
X4 Pharmaceuticals, Inc
XFOR · Biological Products, (No Diagnostic Substances)
Syndax Pharmaceuticals Inc
SNDX · Pharmaceutical Preparations
Syndax Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for hematologic malignancies and other serious diseases.
Lexeo Therapeutics, Inc.
LXEO · Biological Products, (No Diagnostic Substances)
Lexeo Therapeutics is a U.S.-based clinical-stage biotechnology company developing gene therapy candidates for serious cardiovascular and neuromuscular diseases.
Last updated: 24/09/2026